
News|Articles|February 13, 2019
Gamifant for Primary Hemophagocytic Lymphohistiocytosis
Author(s)Drew Boxler
Advertisement
Gamifant (emapalumab-lzsg, Sobi)
Indications: patients with primary hemophagocytic lymphohistiocytosis (HLH) with refractory, recurrent or progressive disease or intolerance with conventional HLH therapy.
Dosage: 1 mg/kg as an intravenous infusion over 1 hour twice per week; Administer dexamethasone concomitantly with GAMIFANT.
Contraindications:None
Newsletter
Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Drug Topics
1
Impact of Pharmacy Closures Reaches Far Beyond Medication Access
2
Mavacamten Shows Improvements for Pediatric Obstructive Hypertrophic Cardiomyopathy
3
Pharmacy Partner in Creating Efficiency, Profitability, and Positive Patient Outcomes
4
National Pharmacist Day: Advocating for Provider Status Through Collaboration
5










































































































































































































